Nenadić, I.; Staber, J.; Dreier, S.; Simons, G.; Schildgen, V.; Brockmann, M.; Schildgen, O.
Cost Saving Opportunities in NSCLC Therapy by Optimized Diagnostics. Cancers 2017, 9, 88.
https://doi.org/10.3390/cancers9070088
AMA Style
Nenadić I, Staber J, Dreier S, Simons G, Schildgen V, Brockmann M, Schildgen O.
Cost Saving Opportunities in NSCLC Therapy by Optimized Diagnostics. Cancers. 2017; 9(7):88.
https://doi.org/10.3390/cancers9070088
Chicago/Turabian Style
Nenadić, Ilija, Janine Staber, Susanne Dreier, Guus Simons, Verena Schildgen, Michael Brockmann, and Oliver Schildgen.
2017. "Cost Saving Opportunities in NSCLC Therapy by Optimized Diagnostics" Cancers 9, no. 7: 88.
https://doi.org/10.3390/cancers9070088
APA Style
Nenadić, I., Staber, J., Dreier, S., Simons, G., Schildgen, V., Brockmann, M., & Schildgen, O.
(2017). Cost Saving Opportunities in NSCLC Therapy by Optimized Diagnostics. Cancers, 9(7), 88.
https://doi.org/10.3390/cancers9070088